Leramistat clinical trials
How each study uses leramistat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the leramistat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Modern Biosciences Ltd (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses leramistat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult SubjectsRecruitingPhase 1Modern Biosciences LtdNCT06379958Written as leramistat 40mg
- Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RACompletedPhase 2Modern Biosciences LtdNCT05460832Written as MBS2320 5 mg
- A Study to Investigate Leramistat in Patients With IPFWithdrawnPhase 2Modern Biosciences LtdNCT05951296Written as Leramistat
- Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid ArthritisCompletedPhase 2Modern Biosciences LtdNCT03139136Written as MBS2320
Given beside what is tested · 1 — leramistat is usual care or a partner of the new treatment
Codes
What other systems call leramistat · ClinicalTrials.gg INT014621
- UNII (FDA) 38E2HYD3AWLERAMISTATOne source FDA
- NCI Thesaurus C203233LeramistatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 38E2HYD3AW | LERAMISTAT | One source FDA |
| NCI Thesaurus | C203233 | Leramistat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.